|Dr. Briggs W. Morrison M.D.||CEO & Director||848.43k||N/A||1960|
|Mr. Michael A. Metzger||Pres, COO & Director||795.35k||N/A||1971|
|Dr. Michael L. Meyers||Chief Medical Officer & Sr. VP||599.3k||N/A||1951|
|Dr. Peter Ordentlich||Co-Founder & Chief Scientific Officer||N/A||N/A||1969|
|Dr. Richard A. Heyman||Co-Founder||N/A||N/A||1957|
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 7.